Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbott

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott

4Q Revenues: $6.2 billion (+2.8%)

4Q Loss: $476.2 million (earnings were $974.6 million in 4Q2005)

FY Revenues: $22.5 billion (flat)

FY Earnings: $1.7 billion (-49%)

Comments: Adjusting both periods for the amendment of the Boehringer Ingelheim distribution agreement, net sales increased by 14.5% for the quarter and 11.6% for the year. Humira sales were $370 million in the quarter, up 31% and $1.2 billion for the year, up 38%. Depakote sales were $384 million in the quarter, up 15% and $1.2 billion for the year, up 18.5%. In the quarter, earnings exclude after-tax charges of $1.3 billion for acquired in process and collaborations R&D primarily related to the Kos acquisition and $110 million for cost reduction initiatives. For the year, earnings exclude charges of $1.7 billion for acquired in-process and collaborations R&D, $141 million for cost reduction initiatives, $220 million for integration activities primarily related to the Guidant acquisition. R&D spending was $596.2 million in the quarter, up 22% and $2.3 billion for the year, up 24%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters